Novo Nordisk’s Ozempic (semaglutide) Receives the US FDA’s Approval for Reduction in MACE in Patients with Type 2 Diabetes

 Novo Nordisk’s Ozempic (semaglutide) Receives the US FDA’s Approval for Reduction in MACE in Patients with Type 2 Diabetes

Novo Nordisk’s Ozempic (semaglutide) Receives the US FDA’s Approval for Reduction in MACE in Patients with Type 2 Diabetes

Shots:

  • The approval is based on SUSTAIN 6 CVOT study assessing Ozempic (0.5mg /1mg, inj.) vs PBO + SOC in 3297 patients with T2D with established CVDs
  • The SUSTAIN 6 study results: @2yrs. 26% reduction in risk of MACE; primary composite outcome (6.6% vs 8.9%)
  • Additionally, Rybelsus (semaglutide, 7mg/14mg) prescribing information has been updated in section 14 (clinical studies) to include an analysis from 1EPs of the PIONEER 6 CVOT study demonstrating the hazard ratio for time to first three-component MACE

Click here ­to­ read full press release/ article | Ref: Novo Nordisk | Image: The Pharma Letter

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post